Clinical presentation, treatment, and complications of malignant hyperthermia in North America from 1987 to 2006.
BACKGROUND
We analyzed cases of malignant hyperthermia (MH) reported to the North American MH Registry for clinical characteristics, treatment, and complications.


METHODS
Our inclusion criteria were as follows: AMRA (adverse metabolic/musculoskeletal reaction to anesthesia) reports between January 1, 1987 and December 31, 2006; "very likely" or "almost certain" MH as ranked by the clinical grading scale; United States or Canadian location; and more than one anesthetic drug given. An exclusion criterion was pathology other than MH; for complication analysis, patients with unknown status or minor complications attributable to dantrolene were excluded. Wilcoxon rank sum and Pearson exact chi(2) tests were applied. A multivariable model of the risk of complications from MH was created through stepwise selection with fit judged by the Hosmer-Lemeshow statistic.


RESULTS
Young males (74.8%) dominated in 286 episodes. A total of 6.5% had an MH family history; 77 of 152 patients with MH reported >or=2 prior unremarkable general anesthetics. In 10 cases, skin liquid crystal temperature did not trend. Frequent initial MH signs were hypercarbia, sinus tachycardia, or masseter spasm. In 63.5%, temperature abnormality (median maximum, 39.1 degrees C) was the first to third sign. Whereas 78.6% presented with both muscular abnormalities and respiratory acidosis, only 26.0% had metabolic acidosis. The median total dantrolene dose was 5.9 mg/kg (first quartile, 3.0 mg/kg; third quartile, 10.0 mg/kg), although 22 patients received no dantrolene and survived. A total of 53.9% received bicarbonate therapy. Complications not including recrudescence, cardiac arrest, or death occurred in 63 of 181 patients (34.8%) with MH. Twenty-one experienced hematologic and/or neurologic complications with a temperature <41.6 degrees C (human critical thermal maximum). The likelihood of any complication increased 2.9 times per 2 degrees C increase in maximum temperature and 1.6 times per 30-minute delay in dantrolene use.


CONCLUSIONS
Elevated temperature may be an early MH sign. Although increased temperature occurs frequently, metabolic acidosis occurs one-third as often. Accurate temperature monitoring during general anesthetics and early dantrolene administration may decrease the 35% MH morbidity rate.
Larach
Marilyn Green
MG
Department of Anesthesiology H187, The North American Malignant Hyperthermia Registry of MHAUS, Penn State College of Medicine, Hershey, Pennsylvania 17033, USA. mlarach@gmail.co
Gronert
Gerald A
GA
Allen
Gregory C
GC
Brandom
Barbara W
BW
Lehman
Erik B
EB
D000293:Adolescent; D000328:Adult; D000368:Aged; D000777:Anesthetics / Q000009:adverse effects; D002648:Child; D002675:Child, Preschool; D003620:Dantrolene / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007223:Infant; D008297:Male; D008305:Malignant Hyperthermia / Q000150:complications / Q000175:diagnosis / Q000628:therapy; D008875:Middle Aged; D009125:Muscle Relaxants, Central / Q000627:therapeutic use; D055815:Young Adult
D000777:Anesthetics; D009125:Muscle Relaxants, Central; D003620:Dantrolene